Beta společnosti AC Immune SA
Jaká je hodnota metriky Beta společnosti AC Immune SA?
Hodnota metriky Beta společnosti AC Immune SA je 0.82
Jaká je definice metriky Beta?
BETA koeficient vyjadřuje, zda je akcie více či méně volatilní než trh jako celek. Beta menší než 1 znamená, že akcie jsou méně volatilní než trh, zatímco beta větší než 1 znamená, že akcie jsou volatilnější. Volatilita se měří pomocí fluktuace ceny akcie.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností AC Immune SA
Čemu se věnuje společnost AC Immune SA?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Firmy s metrikou beta podobnou společnosti AC Immune SA
- Hodnota metriky Beta společnosti Punjab National Bank je 0.82
- Hodnota metriky Beta společnosti ALSO AG je 0.82
- Hodnota metriky Beta společnosti Pantronics je 0.82
- Hodnota metriky Beta společnosti RIWI je 0.82
- Hodnota metriky Beta společnosti SFL Ltd je 0.82
- Hodnota metriky Beta společnosti Tantech Ltd je 0.82
- Hodnota metriky Beta společnosti AC Immune SA je 0.82
- Hodnota metriky Beta společnosti Greenlam Industries je 0.82
- Hodnota metriky Beta společnosti POCL Enterprises je 0.82
- Hodnota metriky Beta společnosti Tech Mahindra je 0.82
- Hodnota metriky Beta společnosti Southern Arc Minerals je 0.82
- Hodnota metriky Beta společnosti TSS je 0.82
- Hodnota metriky Beta společnosti LifeTech Scientific je 0.82